# Sandra M. Swain

Source: https://onco.cc/people/sandra-swain/  
OnCo record `sandra-swain` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led CLEOPATRA, which showed dual HER2 blockade with pertuzumab gives an unprecedented 16-month survival gain in metastatic disease.

## Summary

Sandra Swain was principal investigator of CLEOPATRA, the trial establishing pertuzumab plus trastuzumab and docetaxel as first-line therapy for HER2-positive metastatic breast cancer with a median survival of 56 months. She has led NSABP trials, chaired ASCO, and published extensively on anthracycline cardiotoxicity. Her current work covers HER2-directed therapy sequencing and disparities in trial access.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: breast; her2; trialist
- Role: Professor of Medicine and Associate Dean for Research Development, Georgetown University Medical Center
- Specialisms: HER2-positive breast cancer; Anti-HER2 combinations; Cardio-oncology; Inflammatory breast cancer

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Sandra_M._Swain
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Swain%20SM%5BAuthor%5D%20pertuzumab

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- technologies: [Cardio-oncology](https://onco.cc/technologies/cardio-oncology/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [HER2](https://onco.cc/targets/her2/)
- drugs: [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- institutions: [Georgetown Lombardi Comprehensive Cancer Center](https://onco.cc/institutions/georgetown-lombardi/)
- trials: [CLEOPATRA](https://onco.cc/trials/cleopatra/)

---
JSON: https://onco.cc/api/v1/entities/sandra-swain.json